ArticleAmerican journal of respiratory and critical care medicine2014
Circulating fibrocytes as biomarker of prognosis in Hermansky-Pudlak syndrome.
Article in American journal of respiratory and critical care medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial.JCI insight · 2023Trial
- Impairment of Renal Function in Hermansky-Pudlak Syndrome.American journal of nephrology · 2025Article
- A roadmap for developing and engineeringBiophysics reviews · 2023Review
- The world of rare interstitial lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Circulating fibrocyte levels correlate with infarct size in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention.American heart journal plus : cardiology research and practice · 2021Article
- Hermansky-Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2021Article
- Hermansky-Pudlak Syndrome and Lung Disease: Pathogenesis and Therapeutics.Frontiers in pharmacology · 2021Review
- Automated Digital Quantification of Pulmonary Fibrosis in Human Histopathology Specimens.Frontiers in medicine · 2021Article
- Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease.ERJ open research · 2020Article
- Circulating fibrocytes traffic to the lung in murine acute lung injury and predict outcomes in human acute respiratory distress syndrome: a pilot study.Molecular medicine (Cambridge, Mass.) · 2020Article
- Effects of high glucose on proliferation and function of circulating fibrocytes: Involvement of CXCR4/SDF‑1 axis.International journal of molecular medicine · 2019Article
- Fibrocytes are increased in lung and peripheral blood of patients with idiopathic pulmonary fibrosis.Respiratory research · 2018Article
- Circulating fibrocytes as biomarkers of impaired lung function in adults with sickle cell disease.Blood advances · 2017Article
- Pulmonary Fibrosis in Hermansky-Pudlak Syndrome.Annals of the American Thoracic Society · 2016Review
- Hermansky-Pudlak Syndrome.Clinics in chest medicine · 2016Review
- Circulating fibrocytes as predictors of adverse events in unstable angina.Translational research : the journal of laboratory and clinical medicine · 2016Article
- Number, activation, and differentiation of circulating fibrocytes correlate with asthma severity.The Journal of allergy and clinical immunology · 2016Article
- Article
- Reply: circulating fibrocytes as a biomarker of prognosis in Hermansky-Pudlak syndrome.American journal of respiratory and critical care medicine · 2015Article
- Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis.Frontiers of medicine · 2014Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
rationaleThe rate of progression of most interstitial lung diseases (ILD) is unpredictable. Fibrocytes are circulating bone marrow-derived cells that have been implicated in the pathogenesis of lung fibrosis. Hermansky-Pudlak syndrome (HPS), a genetic cause of ILD in early adulthood, allows for study of biomarkers of ILD in a homogeneous population at near-certain risk of developing fibrotic lung disease.
objectivesTo test the hypothesis that, in subjects with HPS, the number or phenotype of circulating fibrocytes predicts progression and outcome of ILD.
methodsWe measured circulating fibrocyte counts and chemokine levels in a cohort of subjects with HPS and healthy control subjects and correlated the results to disease outcome. MEASUREMENTS AND MAIN
resultsIn a cross-sectional analysis, peripheral blood fibrocyte concentrations were markedly elevated in a subset of subjects with HPS who had ILD but not subjects without lung disease or normal control subjects. The blood concentration of fibrocytes expressing the chemokine receptor CXCR4 correlated significantly with the plasma concentration of the CXCR4 ligand, CXCL12. In a longitudinal study, we found marked episodic elevations in circulating fibrocyte counts over a median follow-up period of 614 days. Elevations in both maximal values and final values of peripheral blood CXCR4(+) fibrocyte concentration were strongly associated with death from ILD.
conclusionsCXCR4(+) fibrocyte concentration may be useful as a biomarker for outcome of ILD in subjects with HPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.